Stifel Financial Corp Purchases 53,673 Shares of Evolus, Inc. (NASDAQ:EOLS)

Stifel Financial Corp increased its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 37.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 197,697 shares of the company's stock after buying an additional 53,673 shares during the quarter. Stifel Financial Corp owned 0.31% of Evolus worth $2,183,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. KBC Group NV acquired a new position in shares of Evolus during the fourth quarter worth $49,000. IFP Advisors Inc raised its stake in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after buying an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Evolus during the 4th quarter valued at about $106,000. Quantbot Technologies LP bought a new position in shares of Evolus during the 4th quarter worth approximately $118,000. Finally, Tradition Wealth Management LLC grew its holdings in Evolus by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock worth $144,000 after purchasing an additional 2,000 shares during the period. Institutional investors and hedge funds own 90.69% of the company's stock.

Evolus Price Performance

Shares of EOLS stock traded down $0.23 on Friday, reaching $9.86. The company's stock had a trading volume of 1,028,578 shares, compared to its average volume of 677,259. The stock's 50 day simple moving average is $11.75 and its 200-day simple moving average is $12.62. Evolus, Inc. has a 12-month low of $8.67 and a 12-month high of $17.82. The company has a market capitalization of $635.68 million, a P/E ratio of -10.84 and a beta of 1.11. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Insider Buying and Selling

In other Evolus news, insider David Moatazedi sold 6,251 shares of the business's stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $12.40, for a total value of $77,512.40. Following the transaction, the insider now owns 508,619 shares in the company, valued at approximately $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the transaction, the director now owns 32,183 shares in the company, valued at approximately $418,057.17. This represents a 28.59 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,575 shares of company stock worth $794,369. Corporate insiders own 5.90% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on EOLS. BTIG Research assumed coverage on Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. Barclays boosted their price target on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Finally, Needham & Company LLC restated a "buy" rating and issued a $22.00 target price on shares of Evolus in a report on Thursday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $23.75.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.